The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
| Autor: | Andrew Carvalho, Kim Tang, Christopher J. Winrow, John R. Hadcock, Sarah Jacobson, Jenny Tobin, Elisabeth Lonie, Sylvie G. Bernier, Thomas W.-H. Lee, Susana S. Correia, Rennie Glen Robert, Chad D. Schwartzkopf, Joon Jung, Peter Germano, Guang Liu, Juli E. Jones, Mark G. Currie, Paul Allan Renhowe, Rajesh R. Iyengar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.drug_class Inflammation RM1-950 Pharmacology Neuroprotection Nitric oxide 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine nitric oxide medicine Pharmacology (medical) Donepezil Cyclic guanosine monophosphate Original Research business.industry Neurodegeneration neurodegeneration Long-term potentiation cGMP (cyclic GMP) medicine.disease Receptor antagonist 030104 developmental biology chemistry neuroprotection Therapeutics. Pharmacology medicine.symptom business 030217 neurology & neurosurgery soluble guanylate cyclase (sGC) medicine.drug |
| Zdroj: | Frontiers in Pharmacology, Vol 12 (2021) Frontiers in Pharmacology |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2021.656561/full |
| Popis: | Effective treatments for neurodegenerative diseases remain elusive and are critically needed since the burden of these diseases increases across an aging global population. Nitric oxide (NO) is a gasotransmitter that binds to soluble guanylate cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP). Impairment of this pathway has been demonstrated in neurodegenerative diseases. Normalizing deficient NO-cGMP signaling could address multiple pathophysiological features of neurodegenerative diseases. sGC stimulators are small molecules that synergize with NO, activate sGC, and increase cGMP production. Many systemic sGC stimulators have been characterized and advanced into clinical development for a variety of non-central nervous system (CNS) pathologies. Here, we disclose the discovery of CY6463, the first brain-penetrant sGC stimulator in clinical development for the treatment of neurodegenerative diseases, and demonstrate its ability to improve neuronal activity, mediate neuroprotection, and increase cognitive performance in preclinical models. In several cellular assays, CY6463 was demonstrated to be a potent stimulator of sGC. In agreement with the known effects of sGC stimulation in the vasculature, CY6463 elicits decreases in blood pressure in both rats and mice. Relative to a non-CNS penetrant sGC stimulator, rodents treated with CY6463 had higher cGMP levels in cerebrospinal fluid (CSF), functional-magnetic-resonance-imaging-blood-oxygen-level-dependent (fMRI-BOLD) signals, and cortical electroencephalographic (EEG) gamma-band oscillatory power. Additionally, CY6463 improved cognitive performance in a model of cognitive disruption induced by the administration of a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. In models of neurodegeneration, CY6463 treatment increased long-term potentiation (LTP) in hippocampal slices from a Huntington’s disease mouse model and decreased the loss of dendritic spines in aged and Alzheimer’s disease mouse models. In a model of diet-induced obesity, CY6463 reduced markers of inflammation in the plasma. Furthermore, CY6463 elicited an additive increase in cortical gamma-band oscillatory power when co-administered with donepezil: the standard of care in Alzheimer’s disease. Together, these data support the clinical development of CY6463 as a novel treatment for neurodegenerative disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|